CELL & GENE THERAPY INSIGHTS

Scale-up and scale-out - what do we really need and how will we get there?

Guest Editor:
Jan Thirkettle, Chief Executive Officer at Transine Therapeutics
Jan Thirkettle
Chief Executive Officer at Transine Therapeutics
Chief Executive Officer of Transine Therapeutics, UK based biotech developing SINEUPs (a novel lncRNA platform which upregulates protein expression) in ocular and neurodegenerative diseases. He was previously Chief Development Officer at Freeline, a clinical phase AAV gene therapy company with a novel AAV capsid platform. Jan has extensive experience in the development and commercialisation of novel platforms including NCEs, natural products, biologics and gene therapies, and has played a role in launching products in all these classes. Prior to joining Freeline Jan led the establishment of GSK&rsquo;s Cell and Gene Therapy platform and was responsible for CMC/supply for Strimvelis, the first&nbsp;<em>ex vivo</em> gene therapy to receive an EU Marketing Authorisation Application. Jan holds an MA in Chemistry and a PhD in Biological Chemistry from Oxford University.

Scale-up and scale-out: what do we really need and how...

J Thirkettle
Jan Thirkettle
Chief Executive Officer at Transine Therapeutics
Chief Executive Officer of Transine Therapeutics, UK based biotech developing SINEUPs (a novel lncRNA platform which upregulates protein expression) in ocular and neurodegenerative diseases. He was previously Chief Development Officer at Freeline, a clinical phase AAV gene therapy company with a novel AAV capsid platform. Jan has extensive experience in the development and commercialisation of novel platforms including NCEs, natural products, biologics and gene therapies, and has played a role in launching products in all these classes. Prior to joining Freeline Jan led the establishment of GSK’s Cell and Gene Therapy platform and was responsible for CMC/supply for Strimvelis, the first ex vivo gene therapy to receive an EU Marketing Authorisation Application. Jan holds an MA in Chemistry and a PhD in Biological Chemistry from Oxford University.
15 October 2021
Foreword

From start-up to scale-up: a journey through AAV process...

K Mouillesseaux
Kevin Mouillesseaux
Director, Process Development at StrideBio Inc
Kevin Mouillesseaux, PhD, joined StrideBio in October 2016, when the entire company could take conference calls around a single Bluetooth speakerphone. Dr Mouillesseaux leads StrideBio’s upstream and downstream process development efforts and engineered the company’s proprietary suspension producer cell line, HEKMo. Before coming to StrideBio, Dr Mouillesseaux worked in Biogen’s small-scale upstream process development group. As an academic scientist, Dr Mouillesseaux earned his doctorate at the University of California, Los Angeles, using molecular and cellular biology and genetics to study endothelial cell biology in the zebrafish model organism. During his postdoctoral fellowship at the University of North Carolina at Chapel Hill, Dr Mouillesseaux leveraged those same skills to study intercellular communication during cell fate determination.
5 October 2021
Viewpoint

Improving the yield of rAAV manufacturing with HeLa producer...

M Fuller
Matthew Fuller
PhD, Ultragenyx Gene Therapy
5 October 2021
Editorial

Viral vector gene delivery: balancing safety, efficacy...

T Gerritzen
Thijs Gerritzen
Principal Scientist Process Development, Amarna Therapeutics, Leiden, The Netherlands
THIJS GERRITZEN is a curious biotechnologist currently working as Principal Scientist Process Development at Amarna Therapeutics in Leiden, The Netherlands. His work focuses on the development of a high-yielding and scalable manufacturing process for replication deficient SV40-based gene therapies. Amarna Therapeutics is a Dutch biotech company, which develops next-generation gene therapies, based on a new proprietary, non-immunogenic viral vector and production platform. Dr Gerritzen holds a PhD in BioProcess Engineering from Wageningen University in a joint project with the BioProcess Engineering group and Intravacc. During his industrial PhD project, he studied the production of bioengineered bacterial outer membrane vesicles as vaccine platform. Besides working as a scientist, Thijs is a rookie dad and likes to spend his time with his family and to explore the world with his 6-month old.
1 October 2021
Viewpoint

Expert Roundtable: evolution in AAV process development:...

A Becerra,
Alejandro Becerra
Principal Applications Scientist and Global Purification Technical Lead, Thermo Fisher Scientific
Dr. Alejandro Becerra is a Principal Applications Scientist and Global Purification Technical Lead. Alejandro has over 14 years of experience in downstream processing and customer support having worked as Purification Team Manager and other bioprocess engineering roles prior to joining Thermo Fisher Scientific in 2018. Dr. Becerra is a subject matter expert in preparative chromatography with expertise in the development, optimization and scale-up of antibody, recombinant protein and viral vector purification processes. Alejandro holds a Ph.D. in Chemical Engineering from Cornell University.
M Hebben,
Matthias Hebben
Vice President of Technology Development, LogicBio Therapeutics
Matthias has served as VP Technology Development since February 2019. Before that, he served as Director of AAV Technology Development and head of bioprocess development at Genethon for 6 years, where he managed the design and scale up of manufacturing processes for AAV and LV vectors. Prior to his role at Genethon, Matthias was Director of the Virology Unit at Vivalis for 4 years. Before that, he occupied several roles in the animal health industry at Intervet Schering Plough and Virbac between 1999 and 2008. Matthias has a PhD in molecular biology from the University of Nice Sophia Antipolis (France) and a bioprocess engineer degree from the University of Strasbourg (France).
M Mercaldi
Michael Mercaldi
Senior Director of Downstream Process Development, Homology Medicines
Michael is the Director of Purification Process Development at Homology Medicines and is responsible for leading the development of Homology’s purification manufacturing processes for their gene therapy and gene editing programs. He has worked purification process development throughout his career at MedImmune/AstraZeneca, Merrimack Pharmaceuticals and Codiak Biosciences before joining Homology. He holds a BS in Chemical Engineering from the Rensselaer Polytechnic Institute and a PhD in Biochemical Engineering from Tufts University
15 October 2021
Expert Roundtable Video

Expert Roundtable: evolution in AAV process development:...

A Becerra,
Alejandro Becerra
Principal Applications Scientist and Global Purification Technical Lead, Thermo Fisher Scientific
Dr. Alejandro Becerra is a Principal Applications Scientist and Global Purification Technical Lead. Alejandro has over 14 years of experience in downstream processing and customer support having worked as Purification Team Manager and other bioprocess engineering roles prior to joining Thermo Fisher Scientific in 2018. Dr. Becerra is a subject matter expert in preparative chromatography with expertise in the development, optimization and scale-up of antibody, recombinant protein and viral vector purification processes. Alejandro holds a Ph.D. in Chemical Engineering from Cornell University.
M Hebben,
Matthias Hebben
Vice President of Technology Development, LogicBio Therapeutics
Matthias has served as VP Technology Development since February 2019. Before that, he served as Director of AAV Technology Development and head of bioprocess development at Genethon for 6 years, where he managed the design and scale up of manufacturing processes for AAV and LV vectors. Prior to his role at Genethon, Matthias was Director of the Virology Unit at Vivalis for 4 years. Before that, he occupied several roles in the animal health industry at Intervet Schering Plough and Virbac between 1999 and 2008. Matthias has a PhD in molecular biology from the University of Nice Sophia Antipolis (France) and a bioprocess engineer degree from the University of Strasbourg (France).
M Mercaldi
Michael Mercaldi
Senior Director of Downstream Process Development, Homology Medicines
Michael is the Director of Purification Process Development at Homology Medicines and is responsible for leading the development of Homology’s purification manufacturing processes for their gene therapy and gene editing programs. He has worked purification process development throughout his career at MedImmune/AstraZeneca, Merrimack Pharmaceuticals and Codiak Biosciences before joining Homology. He holds a BS in Chemical Engineering from the Rensselaer Polytechnic Institute and a PhD in Biochemical Engineering from Tufts University
15 October 2021
Expert Roundtable
  • Platform optimization for efficient AAV purification – insights from...

    N Laroudie,
    V Ravault
    Nicolas Laroudie
    Nicolas Laroudie
    Senior Field Application Specialist, Purification at Thermo Fisher Scientific
    Vincent Ravault
    Vincent Ravault
    Technician, Process Development and Industrialization Department
    26 Oct 2021
    3
    Days
    6
    Hrs
    4
    Min
    Register
  • Considerations for developing scalable and efficient collection network...

    L Anderson,
    S Butler
    Lacey Anderson
    Lacey Anderson
    Senior Manager, Collection Network Management at Be The Match BioTherapies
    Sara Butler
    Sara Butler
    at Nebraska Medicine
    28 Oct 2021
    6
    Days
    0
    Hrs
    31
    Min
    Register
  • Achieving high non-viral transfection performance for cell therapy processing

    N Andronikou,
    T Roth,
    J Fraietta
    Nektaria Andronikou
    Nektaria Andronikou
    Senior R&D Manager at Thermo Fisher Scientific
    Theodore Roth
    Theodore Roth
    Co-founder at Arsenal Biosciences
    Joseph Fraietta
    Joseph Fraietta
    Assistant Professor - Microbiology at University of Pennsylvania
    16 Nov 2021
    24
    Days
    6
    Hrs
    4
    Min
    Register
  • Magnetic selection for consistent cellular starting material in autologous...

    K Olsen,
    R Perret
    Kenneth Olsen
    Kenneth Olsen
    Senior R&D Scientist, Personalized Medicine Business Unit at Lonza
    Rachel Perret
    Rachel Perret
    Team Leader, CAR T-cell Research Program at Malaghan Institute of Medical Research
    23 Nov 2021
    31
    Days
    6
    Hrs
    4
    Min
    Register
  • Enabling clinical grade manufacturing of gene-engineered NK cells

    N Moker,
    E Ullrich,
    R Rizwan
    Nina Moker
    Nina Moker
    R&D Scientist at Miltenyi Biotec
    Evelyn Ullrich
    Evelyn Ullrich
    Arbeitsgruppe Zelluläre Immunologie
    Romee Rizwan
    Romee Rizwan
    M.D at Harvard University
    30 Nov 2021
    38
    Days
    6
    Hrs
    4
    Min
    Register
  • Advancing engineered cell and gene therapy with precision gene editing

    J Harbottle,
    D Maddalo
    Jennifer Harbottle
    Jennifer Harbottle
    Senior Scientist, R&D, Cell and Gene Therapy at Horizon Discovery
    Danilo Maddalo
    Danilo Maddalo
    Group Leader, Translational Oncology at Genentech, Inc
    11 Nov 2021
    19
    Days
    6
    Hrs
    4
    Min
    Register
  • Automated cell expansion: Current technologies and trends

    A Kilgore,
    D Sethi
    Augustus Kilgore
    Augustus Kilgore
    Senior Global Consultant at Terumo BCT
    Dalip Sethi
    Dalip Sethi
    Manager, Senior Scientist at Terumo BCT
    9 Nov 2021
    17
    Days
    6
    Hrs
    4
    Min
    Register
  • The therapeutic gene editing solution – cell therapy for solid tumors

    B Sasu,
    P Sivakumar,
    J Trager et al.
    Barbra Sasu
    Barbra Sasu
    Chief Scientific Officer at Allogene Therapeutics, Inc
    Pallavur Sivakumar
    Pallavur Sivakumar
    Scientific Vice President and Head of Discovery Immuno-Oncology and Cell Therapy Thematic Research Center at Bristol Myers Squibb
    James Trager
    James Trager
    Chief Scientific Officer at Nkarta Therapeutics, Inc
    Jennifer Harbottle
    Jennifer Harbottle
    Senior Scientist, R&D, Cell and Gene Therapy at Horizon Discovery
    30 September 2021
    Watch now
  • Optimization of AAV production for high-yielding and scalable GMP processes

    C Wartel-Weill,
    M Porte,
    B Kondragunta et al.
    Claire Wartel-Weill
    Claire Wartel-Weill
    Director, Quality & Compliance at Polyplus-transfection
    Mathieu Porte
    Mathieu Porte
    Project Leader at Polyplus-transfection
    Bhargavi Kondragunta
    Bhargavi Kondragunta
    Director, Internal R&D and Product Development at Catalent Cell and Gene therapy
    George Buchman
    George Buchman
    Vice President, Pre-Clinical and Process Development at Catalent Cell & Gene Therapy
    20 October 2021
    Watch now
  • cGMP manufacturing made easy – a case study by ElevateBio

    M Paglia,
    S Eaker
    Michael Paglia
    Michael Paglia
    Senior Vice President - CMC Operations at Elevatebio
    Shannon Eaker
    Shannon Eaker
    Cell Therapy Enterprise Technical Leader
    14 October 2021
    Watch now
  • Gain deeper insights into the mechanisms of immune cell killing of tumor cells:...

    C Souders,
    T Dale,
    N Bevan et al.
    Colby Souders
    Colby Souders
    Chief Scientific Officer at Abveris
    Tim  Dale
    Tim Dale
    Head of BioAnalytics Applications at Sartorius
    Nicola Bevan
    Nicola Bevan
    Manager of Cell Imaging Applications at Sartorius
    Jeffrey Skolnik
    Jeffrey Skolnik
    Senior Vice President, Clinical Development at Inovio Pharmaceuticals, Inc
    6 October 2021
    Watch now
  • GMP manufacturing for exosome-based therapies: the critical role of analytics...

    M Langtry,
    D Zocco
    Marcos Langtry
    Marcos Langtry
    Head of Allogeneic Cell Therapy - Commercial Development at Lonza
    Davide Zocco
    Davide Zocco
    Head of Allogeneic Cell Therapy Commercial Development at Lonza
    28 September 2021
    Watch now
  • Get your non-viral T cell engineering process ready for clinical manufacturing

    M Rietenbach,
    S Wild,
    K Patel
    Melanie Rietenbach
    Melanie Rietenbach
    Global Product Manager at Miltenyi Biotec
    Stefan Wild
    Stefan Wild
    Senior Manager Research and Development at Miltenyi Biotec
    Kunal Patel
    Kunal Patel
    Process engineering manager at Miltenyi Biotec
    21 September 2021
    Watch now
  • Channel content

    Reports

    FEATURING

    Clinical trials with investigational medicinal products consisting of or containing genetically modified organisms: implementation of Clinical Trials Regulation EU 536/2014

    N Lambot,
    Nathalie Lambot
    Pharma.be
    J Awigena-Cook,
    Jacquelyn Awigena-Cook
    BMS
    T Reimer et al.
    Tatiana Reimer
    Bayer

    The UK’s emerging regulatory framework for point-of-care manufacture: insights from a workshop on advanced therapies

    E Bicudo,
    Edison Bicudo
    Department of Science, Technology, Engineering, and Public Policy, University College London, Shropshire House (4th Floor), 11-20 Capper Street, London WC1E 6JA e.bicudo@ucl.ac.uk
    I Brass,
    Irina Brass
    Department of Science, Technology, Engineering, and Public Policy, University College London, Shropshire House (4th Floor), 11-20 Capper Street, London WC1E 6JA
    P Carmichael et al.
    Penny Carmichael
    Department of Science, Technology, Engineering, and Public Policy, University College London, Shropshire House (4th Floor), 11-20 Capper Street, London WC1E 6JA

    FEATURING

    Evolving technology trends and regulatory pathways in the tissue engineered product space

    W Fodor
    William Fodor
    Chief Scientific Officer, Biostage
    William Fodor received his B.S. degree in Genetics and his Ph.D. degree in Molecular Genetics from The Ohio State University. He then completed his post-doctoral training in Immunobiology at the Yale School of Medicine (Mentor, R.A. Flavell). Dr. Fodor started his industrial career as a founding scientist of Alexion Pharmaceuticals, Inc. During his tenure at Alexion he directed the xenotransplantation, cell and tissue and organ engineering programs and advanced the program to include a pilot manufacturing facility for cell production. Dr. Fodor then moved to academia as an Associate Professor in the Center for Regenerative Biology at the University of Connecticut where he spent 3 years renovating his research to focus on stem cell biology for tissue repair. Dr. Fodor then returned to industry as Senior Director of Product Development at Viacell Inc., where he was responsible for various stem cell product development projects for hematologic indications as well as islet stem cell applications for diabetes. Following his tenure at Viacell, he continued his career in biotechnology as an independent consultant, serving many clients within the regenerative medicine field. Dr. Fodor’s relationship with Biostage was first as a consultant then as the Chief Scientific Officer, his current role.

    Broadening horizons for extracellular vesicles as both therapeutic modality and delivery tool

    J Correia
    Joana Correia
    CEO, Exogenus Therapeutics
    Joana Correia co-founded Exogenus Therapeutics in 2015, after a successful participation in COHiTEC program for technology commercialization. Having been awarded several honors, including three entrepreneurship prizes (Everis Foundation Award, Young Entrepreneur ANJE, and Prémio Empreendedor XXI BPI/CaixaBank), Joana has raised €3.5M in funds for R&D, and is currently a leader in the field of EV–based therapeutics recognized internationally. With a PhD in Human Biology, she dedicated 20 years of her career to R&D in the area of human diseases and healthcare, is inventor of two patents, has several publications in high impact journals, and is invited researcher of the Center for Neuroscience and Cell Biology (CNC, Coimbra, Portugal). Joana is an enthusiastic entrepreneur and activist, with a creative mindset and a strong drive to solve healthcare challenges.

    FEATURING

    Solving the problem of financing one-time treatments with evidence uncertainty: which types of outcomes-based payment models could work best for novel CAR-T therapies in multiple myeloma? A systematic review of the published literature

    C Dietrich,
    Cassidy-Candice Dietrich
    MSc Student, Department of Health Sciences and Medicine, University of Lucerne, Switzerland
    C Hague,
    Clare Hague
    Author for correspondence Honorary Lecturer & Academic Supervisor, Department of Health Sciences and Medicine, University of Lucerne, Switzerland and Therapy Area Market Access Leader, Hematology, Janssen EMEA Region
    S Boes
    Stefan Boes
    Professor of Health Economics, Department of Health Sciences and Medicine, University of Lucerne, Switzerland

    Critical need for establishing value that justifies the current rising costs of cell and gene therapy

    R Maziarz
    Richard T Maziarz, MD
    Professor of Medicine, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97232, USA maziarzr@ohsu.edu

    FEATURING

    Accelerating the development of novel gene therapies for central nervous system diseases

    S Prasad
    Suyash Prasad, MBBS, MSc, MRCP, MRCPCH, FFPM
    Chief Medical Officer and Head of Research and Development, Taysha Gene Therapies
    Suyash Prasad is a Pediatrician, Clinical Development Physician, Translational Scientist and Executive Leader with 20 years’ experience in the biopharmaceutical industry. He currently serves as the Chief Medical Officer and Head of Research and Development at Taysha Gene Therapies, an organization dedicated to developing AAV gene therapy approaches for treating children and adults with severe neurological disease. Suyash graduated in medicine at the University of Newcastle upon Tyne, UK where he received commendations for Pediatrics, Obstetrics and Gynecology, and Medical Ethics. His pediatric training was completed at recognized centers of excellence in the UK and Australia before he moved to industry. His industry career progressed at Eli Lilly, Genzyme, and BioMarin, and more recently he was Chief Medical Officer at the gene therapy company, Audentes Therapeutics (now Astellas Gene Therapies), before moving to Taysha. He is a UK board-certified physician and is a member of the Royal College of Physicians (MRCP) and the Royal College of Paediatrics and Child Health (MRCPCH). Suyash received his Diploma in Pharmaceutical Medicine from the Royal College of Physicians of the UK, and his Masters in Translation Science with distinction from Kings College, London. He is a Fellow of the Faculty of Pharmaceutical Medicine and is a past recipient of the Outstanding Contribution award from the Faculty. Suyash has dedicated his career to the well-being and advocacy of children who are afflicted by rare and severe disease.

    FEATURING

    Boldly de-risking development of impactful cell and gene therapies: the California Stem Cell Agency’s $3B funding model

    S Patel,
    Shyam Patel
    Associate Director, Portfolio Development & Review at California Institute For Regenerative Medicine
    S Talib,
    Sohel Talib
    Director, Therapeutics at California Institute For Regenerative Medicine
    M Millan
    Maria Millan
    Vice President, Therapeutics at California Institute For Regenerative Medicine

    Driving disruptive innovation in the ATMP field

    K Papenfuss
    Kerstin Papenfuss
    Associate Director, Therapeutics at Deep Science Ventures
    Kerstin Papenfuss started her PhD at German Cancer Research Centre and then moved to a lab at Imperial College London to work on novel treatment options within the field of tumor immunology. After a Post Doc in academic drug discovery, she since has spent almost ten years in leadership roles at impact-driven organizations advancing medicine and therapeutics, while also securing an executive MBA and a Women in Business award. Before joining DSV to develop science companies designing more effective therapies, Kerstin was transforming ideas for cutting edge cell and gene therapies into investable propositions at UK’s Cell and Gene Therapy Catapult.

    Latest content

    Magnetic selection for consistent cellular starting material in autologous...

    K Olsen,
    R Perret
    Kenneth Olsen, PhD
    Kenneth Olsen, PhD
    Senior R&D Scientist, Personalized Medicine Business Unit, Lonza
     Rachel Perret, PhD
    Rachel Perret, PhD
    Team Leader, CAR T-cell Research Program, Malaghan Institute of Medical Research
    23 Nov 2021
    31
    Days
    6
    Hrs
    4
    Min
    Register

    Achieving high non-viral transfection performance for cell therapy processing

    N Andronikou,
    T Roth,
    J Fraietta
    Nektaria Andronikou
    Nektaria Andronikou
    Senior R&D Manager, Thermo Fisher Scientific
    Theo Roth Phd, MD
    Theo Roth Phd, MD
    Co-founder, Arsenal Biosciences
    Joe Fraietta
    Joe Fraietta
    Assistant Professor of Microbiology and Scientific Director, University of Pennsylvania
    16 Nov 2021
    24
    Days
    6
    Hrs
    4
    Min
    Register

    Considerations for developing scalable and efficient collection network...

    L Anderson,
    S Butler
    Lacey Anderson
    Lacey Anderson
    Senior Manager, Collection Network Management, Be The Match BioTherapies
    Sara Butler
    Sara Butler
    Network Liaison, Be The Match BioTherapies
    28 Oct 2021
    6
    Days
    0
    Hrs
    31
    Min
    Register

    Platform optimization for efficient AAV purification – insights from...

    N Laroudie,
    V Ravault
    Nicolas Laroudie
    Nicolas Laroudie
    Staff Scientist, Field Applications, Thermo Fisher Scientific
    Vincent Ravault
    Vincent Ravault
    DSP Expert, Process Development and Industrialization Department, YposKesi
    26 Oct 2021
    3
    Days
    6
    Hrs
    4
    Min
    Register

    Are you finishing strong in cell therapy manufacturing? Tackling your final...

    D Sethi,
    A Cunningham
    Dalip Sethi
    Dalip Sethi
    Manager, Senior Scientist at Terumo BCT
    Annie  Cunningham
    Annie Cunningham
    Cell Therapy Laboratory Scientist
    31 August 2021
    Watch now

    The therapeutic gene editing solution – cell therapy for solid tumors

    B Sasu,
    P Sivakumar,
    J Trager et al.
    Barbra Sasu, PhD
    Barbra Sasu, PhD
    Chief Scientific Officer, Allogene Therapeutics
    Pallavur Sivakumar, PhD
    Pallavur Sivakumar, PhD
    Scientific Vice President and Head of Discovery, Immuno-Oncology and Cell Therapy Thematic Research Center, Bristol Myers Squibb
    James Trager, PhD
    James Trager, PhD
    Chief Scientific Officer, Nkarta Therapeutics
    Jennifer Harbottle, PhD
    Jennifer Harbottle, PhD
    Senior Scientist, R&D, Cell and Gene Therapy, Horizon Discovery
    30 September 2021
    Watch now

    Navigating regulations - novel cell therapy platforms and their path to clinical...

    N Bauer,
    N Calhoun,
    A Davies et al.
    Nina Bauer
    Nina Bauer
    Head of Commercial, Gene Editing and Novel Modalities, Merck KGaA
    Natika Calhoun
    Natika Calhoun
    Regulatory Consultant, Merck KGaA
    Anthony Davies
    Anthony Davies
    Founder and CEO, Dark Horse Consulting
    Matt Muldoon
    Matt Muldoon
    Senior Director, Supplier Management, Allogene Therapeutics
    27 May 2021
    Watch now

    Addressing the challenges of purification & quality control in gene therapy

    A Bhattacharya,
    L Kopp,
    K Richter et al.
    Dr. Akash Bhattacharya
    Dr. Akash Bhattacharya
    Senior Application Engineer, Beckman Coulter
    Leisha Kopp
    Leisha Kopp
    Applications Scientist, Mirus Bio
    Klaus Richter, PhD
    Klaus Richter, PhD
    Group Leader AUC, Coriolis Pharma
    Dr. Audrey Chang
    Dr. Audrey Chang
    Vice President of Quality Control and Analytical Service, Vigene Biosciences
    Shawn Sternisha
    Shawn Sternisha
    Senior Field Applications Scientist, Beckman Coulter Life Sciences
    24 June 2021
    Watch now